SCHEMBL1953532

SCHEMBL1953532

Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3nn[nH]c3n2)c(OC(C)C)cc1C1CCNCC1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 20/20 0.77
▸ INSR P06213 9/20 0.77
▸ NPM1 P06748 8/20 0.77
▸ KCNH2 Q12809 3/20 0.75
▸ CYP3A4 P08684 2/20 0.75
▸ PLK4 O00444 1/20 0.72
▸ BUB1B O60566 1/20 0.72
▸ JAK2 O60674 1/20 0.72
▸ ROCK2 O75116 1/20 0.72
▸ ABL1 P00519 1/20 0.72
▸ EGFR P00533 1/20 0.72
▸ NTRK1 P04629 1/20 0.72
▸ LCK P06239 1/20 0.72
▸ FES P07332 1/20 0.72
▸ LYN P07948 1/20 0.72
▸ RET P07949 1/20 0.72
▸ IGF1R P08069 1/20 0.72
▸ ABCB1 P08183 1/20 0.72
▸ MET P08581 1/20 0.72
▸ ROS1 P08922 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1951601 0.95 ALK (0.75) ALKINSRNPM1KCNH2CYP3A4
SCHEMBL1952912 0.91 ALK (0.77) ALKINSRNPM1KCNH2CYP3A4
SCHEMBL1953521 0.89 ALK (0.78) ALKINSRNPM1KCNH2CYP3A4
SCHEMBL1068627 0.88 ALK (0.80) ALKINSRNPM1KCNH2CYP3A4
SCHEMBL1950971 0.87 ALK (0.84) ALKINSRNPM1KCNH2CYP3A4
SCHEMBL1069403 0.87 ALK (1.00) ALKINSRNPM1KCNH2CYP3A4
SCHEMBL1013900 0.86 ALK (1.00) ALKINSRNPM1KCNH2CYP3A4
SCHEMBL1545644 0.86 ALK (0.78) ALKINSRNPM1KCNH2CYP3A4
SCHEMBL18627482 0.86 ALK (1.00) ALKINSRNPM1KCNH2CYP3A4
SCHEMBL1951151 0.85 ALK (0.79) ALKINSRNPM1KCNH2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2271630-B1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2016-03-23 — — EP claimed
EP-2271630-B1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2016-03-23 — — EP disclosed
EP-2271630-B1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2016-03-23 — — EP disclosed
US-8592432-B2 Compounds and compositions as protein kinase inhibitors NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2013-11-26 — — US disclosed
US-20110135668-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2011-06-09 — — US disclosed
US-20110135668-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2011-06-09 — — US disclosed
US-20110135668-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2011-06-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110135668-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS ROS1, INSR, IGF1R ALK 6/4885INSR 2/4885NPM1 2206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback